EBV Related PTCL, NOS
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas (NCT05011058) | Viracta Therapeutics, Inc. | 2021-05-28 |
Track EBV Related PTCL, NOS automatically
Every clearance here is in the API, with alerts when new ones post.